Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von SpringheelJack 

Adverum Biotechnologies Inc. diskutieren

Adverum Biotechnologies Inc.

WKN: A2AJW8 / Symbol: ADVM / Name: Adverum Bio / Aktie / Biotechnologie & medizinische Forschung / Small Cap /

1,38 €
-2,65 %

Sell Avalanche Biotechnologies Inc.

Adverum Biotechnologies, Inc. (NASDAQ: ADVM) is now covered by analysts at LADENBURG THALM/SH SH. They set a "buy" rating on the stock.
Ratings data for ADVM provided by MarketBeat

Adverum Biotechnologies, Inc. (NASDAQ: ADVM) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for ADVM provided by MarketBeat

Einschätzung Buy
Rendite (%) -17,28 %
Kursziel 5,60
Veränderung
Endet am 05.09.24

Adverum Biotechnologies, Inc. (NASDAQ: ADVM) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $6.00 price target on the stock.
Ratings data for ADVM provided by MarketBeat

Einschätzung Buy
Rendite (%) 54,02 %
Kursziel 1,87
Veränderung
Endet am 03.11.24

Adverum Biotechnologies, Inc. (NASDAQ: ADVM) is now covered by analysts at Mizuho. They set a "buy" rating and a $2.00 price target on the stock.
Ratings data for ADVM provided by MarketBeat

Einschätzung Buy
Rendite (%) -32,35 %
Kursziel 3,72
Veränderung
Endet am 06.02.25

Adverum Biotechnologies, Inc. (NASDAQ: ADVM) had its price target raised by analysts at Mizuho from $2.00 to $4.00. They now have a "buy" rating on the stock.
Ratings data for ADVM provided by MarketBeat

Einschätzung Buy
Rendite (%) -8,61 %
Kursziel 3,68
Veränderung
Endet am 19.03.25

Adverum Biotechnologies, Inc. (NASDAQ: ADVM) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $4.00 price target on the stock.
Ratings data for ADVM provided by MarketBeat

Einschätzung Buy
Rendite (%) -
Kursziel 20,55
Veränderung
Endet am 29.04.25

Adverum Biotechnologies, Inc. (NASDAQ: ADVM) had its price target lowered by analysts at Mizuho from $40.00 to $22.00. They now have a "buy" rating on the stock.
Ratings data for ADVM provided by MarketBeat

Einschätzung Buy
Rendite (%) -
Kursziel 28,03
Veränderung
Endet am 30.04.25

Adverum Biotechnologies, Inc. (NASDAQ: ADVM) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $30.00 price target on the stock.
Ratings data for ADVM provided by MarketBeat

Einschätzung Buy
Rendite (%) -
Kursziel 55,13
Veränderung
Endet am 15.05.25

Adverum Biotechnologies, Inc. (NASDAQ: ADVM) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $60.00 price target on the stock.
Ratings data for ADVM provided by MarketBeat